A Phase I/II Study of INCB039110 pus Ibrutinib in Patients with Recurrent or Persistent Diffuse Large B-Cell Lymphoma

Full Title

INCB 39110-206: An Open- Label Phase 1/2 Study of INCB039110 in Combination with Ibrutinib in Subjects with Relapsed or Refractory Diffuse Large B-Cell Lymphoma


Ibrutinib is a drug used to treat diffuse large B-cell lymphoma (DLBCL). It works by blocking a protein inside cancer cells called Bruton’s tyrosine kinase (BTK), which helps cancer cells to live and grow.

INCB039110 is an investigational drug designed to inhibit cancer growth by blocking another kinase enzyme called JAK. In this study, researchers want to evaluate the safety and effectiveness of giving INCB039110 with ibrutinib in patients with DLBCL that has come back or continued to grow despite prior treatment. Both drugs are taken orally (by mouth).


To be eligible for this study, patients must meet several criteria, including but not limited to the following:

  • Patients must have DLBCL that has come back or continued to grow after at least one but no more than three previous regimens of therapy.
  • Patients must have an “activated B-cell” (ABC) subtype of DLBCL.
  • Patients must not be candidates for high-dose chemotherapy and autologous stem cell transplantation.
  • Patients must be able to walk and do routine activities for more than half of their normal waking hours.
  • This study is for patients age 18 and older.

For more information about this study and to inquire about eligibility, please contact Dr. Paul Hamlin at 908-542-3366.